vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Honest Company, Inc. (HNST). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $88.0M, roughly 1.9× Honest Company, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -11.8%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 1.0%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
The Honest Company, Inc. is an American digital-first consumer goods company, based in Los Angeles and founded by actress Jessica Alba, Christopher Gavigan, and Brian Lee. The company had $319 million in 2021 sales, and was valued at roughly $550 million as of February 2022. Carla Vernón, Chief Executive Officer, is one of the first Afro-Latina CEOs of a U.S. publicly traded company. The Honest Company has raised multiple rounds of venture capital, and went public via an initial public offeri...
ESPR vs HNST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $88.0M |
| Net Profit | — | $-23.6M |
| Gross Margin | — | 15.7% |
| Operating Margin | 50.6% | -27.5% |
| Net Margin | — | -26.8% |
| Revenue YoY | 143.7% | -11.8% |
| Net Profit YoY | — | -2813.2% |
| EPS (diluted) | $0.32 | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $88.0M | ||
| Q3 25 | $87.3M | $92.6M | ||
| Q2 25 | $82.4M | $93.5M | ||
| Q1 25 | $65.0M | $97.3M | ||
| Q4 24 | $69.1M | $99.8M | ||
| Q3 24 | $51.6M | $99.2M | ||
| Q2 24 | $73.8M | $93.0M | ||
| Q1 24 | $137.7M | $86.2M |
| Q4 25 | — | $-23.6M | ||
| Q3 25 | $-31.3M | $758.0K | ||
| Q2 25 | $-12.7M | $3.9M | ||
| Q1 25 | $-40.5M | $3.3M | ||
| Q4 24 | — | $-809.0K | ||
| Q3 24 | $-29.5M | $165.0K | ||
| Q2 24 | $-61.9M | $-4.1M | ||
| Q1 24 | $61.0M | $-1.4M |
| Q4 25 | — | 15.7% | ||
| Q3 25 | — | 37.3% | ||
| Q2 25 | — | 40.4% | ||
| Q1 25 | — | 38.7% | ||
| Q4 24 | — | 38.8% | ||
| Q3 24 | — | 38.7% | ||
| Q2 24 | — | 38.3% | ||
| Q1 24 | — | 37.0% |
| Q4 25 | 50.6% | -27.5% | ||
| Q3 25 | -11.4% | 0.3% | ||
| Q2 25 | 8.6% | 3.1% | ||
| Q1 25 | -34.0% | 2.6% | ||
| Q4 24 | -6.4% | -1.0% | ||
| Q3 24 | -31.0% | 0.1% | ||
| Q2 24 | 3.5% | -4.3% | ||
| Q1 24 | 52.5% | -1.5% |
| Q4 25 | — | -26.8% | ||
| Q3 25 | -35.9% | 0.8% | ||
| Q2 25 | -15.4% | 4.1% | ||
| Q1 25 | -62.2% | 3.3% | ||
| Q4 24 | — | -0.8% | ||
| Q3 24 | -57.2% | 0.2% | ||
| Q2 24 | -83.9% | -4.4% | ||
| Q1 24 | 44.3% | -1.6% |
| Q4 25 | $0.32 | $-0.21 | ||
| Q3 25 | $-0.16 | $0.01 | ||
| Q2 25 | $-0.06 | $0.03 | ||
| Q1 25 | $-0.21 | $0.03 | ||
| Q4 24 | $-0.14 | $-0.01 | ||
| Q3 24 | $-0.15 | $0.00 | ||
| Q2 24 | $-0.33 | $-0.04 | ||
| Q1 24 | $0.34 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $89.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $169.7M |
| Total Assets | $465.9M | $225.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $89.6M | ||
| Q3 25 | $92.4M | $71.5M | ||
| Q2 25 | $86.1M | $72.1M | ||
| Q1 25 | $114.6M | $72.8M | ||
| Q4 24 | $144.8M | $75.4M | ||
| Q3 24 | $144.7M | $53.4M | ||
| Q2 24 | $189.3M | $36.6M | ||
| Q1 24 | $226.6M | $33.6M |
| Q4 25 | $-302.0M | $169.7M | ||
| Q3 25 | $-451.4M | $190.2M | ||
| Q2 25 | $-433.5M | $187.0M | ||
| Q1 25 | $-426.2M | $180.4M | ||
| Q4 24 | $-388.7M | $174.3M | ||
| Q3 24 | $-370.2M | $133.9M | ||
| Q2 24 | $-344.2M | $129.7M | ||
| Q1 24 | $-294.3M | $124.8M |
| Q4 25 | $465.9M | $225.4M | ||
| Q3 25 | $364.0M | $241.5M | ||
| Q2 25 | $347.1M | $249.0M | ||
| Q1 25 | $324.0M | $265.3M | ||
| Q4 24 | $343.8M | $247.4M | ||
| Q3 24 | $314.1M | $209.2M | ||
| Q2 24 | $352.3M | $200.2M | ||
| Q1 24 | $373.1M | $198.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $19.3M |
| Free Cash FlowOCF − Capex | — | $18.1M |
| FCF MarginFCF / Revenue | — | 20.5% |
| Capex IntensityCapex / Revenue | 0.0% | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $19.3M | ||
| Q3 25 | $-4.3M | $-504.0K | ||
| Q2 25 | $-31.4M | $-745.0K | ||
| Q1 25 | $-22.6M | $-2.9M | ||
| Q4 24 | $-35.0M | $-16.8M | ||
| Q3 24 | $-35.3M | $15.1M | ||
| Q2 24 | $-7.2M | $2.9M | ||
| Q1 24 | $53.8M | $336.0K |
| Q4 25 | — | $18.1M | ||
| Q3 25 | — | $-624.0K | ||
| Q2 25 | — | $-826.0K | ||
| Q1 25 | — | $-3.0M | ||
| Q4 24 | — | $-17.2M | ||
| Q3 24 | $-35.5M | $15.0M | ||
| Q2 24 | $-7.3M | $2.9M | ||
| Q1 24 | $53.8M | $260.0K |
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | -0.7% | ||
| Q2 25 | — | -0.9% | ||
| Q1 25 | — | -3.1% | ||
| Q4 24 | — | -17.2% | ||
| Q3 24 | -68.7% | 15.1% | ||
| Q2 24 | -9.9% | 3.1% | ||
| Q1 24 | 39.0% | 0.3% |
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.1% | 0.0% | ||
| Q1 24 | 0.1% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.19× | ||
| Q1 25 | — | -0.90× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 91.42× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
HNST
Segment breakdown not available.
